BERKELEY, CA and VANCOUVER, BC–(Marketwired – April 05, 2016) – BriaCell Therapeutics Corp. (“BriaCell” or the “Company”)(TSX VENTURE: BCT) (BCTXF) is very pleased to provide an update in regard to the planned timing of its Phase I/II clinical trial for up to 24 late-stage cancer patients. BriaCell has spent a great deal of time and …
BERKELEY, CA and VANCOUVER, BC–(Marketwired – March 29, 2016) – BriaCell Therapeutics Corp.(“BriaCell” or the “Company”)(TSX VENTURE: BCT) (BCTXF) is very pleased to announce that it has discovered a gene signature potentially explaining why its BriaVax™ cancer vaccine was exceptionally efficacious in a clinical trial subject with stage IV breast cancer. Data will be presented at the Annual …
VANCOUVER, BRITISH COLUMBIA–(Marketwired – Mar 24, 2016) – BriaCell Therapeutics Corp. (BCTXF) (TSX VENTURE:BCT) (the “Company“) announces that Dr. Joseph Wagner has resigned his positions as President and Chief Executive Officer of the Company, effective immediately, in order to pursue other opportunities. Dr. Wagner has also stepped down from the Board. Mr. Rahoul Sharan, Director …
BERKELEY, CA & VANCOUVER, BC – Thursday February 11th 2016: BriaCell Therapeutics Corp (OTCQB:BCTXF) (TSXV: BCT) (“BriaCell”, the “Company”, or “BCT”), an immuno-oncology focused biotechnology company with a proprietary vaccine technology, BriaVaxTM, is pleased to announce that it has hired Mr. Gadi Levin, CPA, MBA, as the Company’s new CFO. Mr. Levin is a highly experienced …
BriaCell Therapeutics Corp. November 4, 2015 11:01 AM BERKELEY, CA and VANCOUVER, BC–(Marketwired – November 04, 2015) – BriaCell Therapeutics Corp (BCTXF) (TSX VENTURE: BCT) (“BriaCell”, the “Company”, or “BCT”) is pleased to announce that the U.S. Food and Drug Administration (FDA) has given final clearance for the Company’s Investigational New Drug (IND) application to …
October 8, 2015 Positive Release Testing Data From First Lot of Vaccine Submitted to FDA; Contract Negotiations Underway With Initial Clinical Site. BriaCell Therapeutics Corp (OTCQB: BCTXF) (TSX VENTURE: BCT) (“BriaCell”, the “Company”, or “BCT”) is pleased to announce that the Company has successfully advanced to the final stages of preparation for the upcoming Phase …
Mon Sep 14, 2015 9:30am EDT BriaCell Launches Development of Companion Diagnostic Product, BriaDx(TM) Also Provides General Corporate Update Including Consolidation of Its Corporate Headquarters and Research Laboratories in San Francisco Bay Area; Attends NYC Biotechnology Conference and Posts Updated Investor Presentation VANCOUVER, BC–(Marketwired – September 14, 2015) – BriaCell Therapeutics Corp (OTCQB: ANCCF) (TSX …
2015 Jul 15 Hired Dr. M. Lacher –Head of R&D -an expert in immuno-oncology & diagnostics
2015 June 24 BriaCell begins trading on the OTCQB (BCTXF)
2015 Jun 16 Signed Definitive Agreement of Manufacturing of BriaVax at cGMP Facility- UC, Davis Health Center